Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy

Health Policy

Volumn 89, Issue 2, 2009, Pages 225-238

  Giorgi Rossi, Paolo ^a   Merito, Monica ^a,b   Borgia, Piero ^a  

^a Agency for Public Health   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

Budget impact; Conjugate pneumococcal vaccine; Cost effectiveness; Economic; Vaccination

Indexed keywords

CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; FINANCING, PERSONAL; HUMANS; IMMUNIZATION PROGRAMS; INFANT; ITALY; MODELS, THEORETICAL; ORGANIZATIONAL CASE STUDIES; PNEUMOCOCCAL VACCINES; PNEUMONIA; VACCINES, CONJUGATE;

EID: 58849099124     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2008.05.016     Document Type: Article

References (59)

1. McIntosh K. Community-acquired pneumonia in children. The New England Journal of Medicine 346 (2002) 429-437
2. Hayden G.F., and Schwartz R.H. Characteristics of earache among children with acute otitis media. American Journal of Diseases of Children 139 (1985) 721-723
3. Di Ciommo V., Russo P., Attanasio E., Di Liso G., Graziani C., and Caprino L. Clinical and economic outcomes of pneumonia in children: a longitudinal observational study in an Italian paediatric hospital. Journal of Evaluation in Clinical Practice 8 (2002) 341-348
4. Esposito S., and Principi N. Epidemiology of meningitis, pneumonia and acute otitis due to Streptococcus pneumoniae in pediatric in Italy. Annali di Igiene 14 6 (Suppl. 7) (2002) 7-16
5. Jefferson T., Ferroni E., Curtale F., Giorgi-Rossi P., and Borgia P. Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old. The Lancet Infectious Diseases 6 (2006) 405-410
6. D'Ancona F., Salmaso S., Barale A., Boccia D., Lopalco P.L., Rizzo C., et al. Incidence of vaccine preventable pneumococcal invasive infections and blood culture practices in Italy. Vaccine 23 (2005) 2494-2500
7. Sangalli M., Palange S., Fabrizi E., Faustini A., and Perucci C.A. Estimating fatality rates of bacterial meningitis from current health databases suggests a different case definition. Results of a follow-up study of bacterial meningitis in Lazio Region, Italy, 1996-2000. Epidemiologia e Prevenzione 29 (2005) 188-194
8. Baraff L.J., Lee S.I., and Schriger D.L. Outcomes of bacterial meningitis in children: a meta-analysis. The Pediatric Infectious Disease Journal 12 (1993) 389-394
9. Lucero M.G., Dulalia V.E., Parreno R.N., Lim-Quianzon D.M., Nohynek H., Makela H., et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age. Cochrane Database of Systematic Reviews 4 (2004)
10. Straetemans M., Sanders E.A., Veenhoven R.H., Schilder A.G., Damoiseaux R.A., and Zielhuis G.A. Pneumococcal vaccines for preventing otitis media. Cochrane Database of Systematic Reviews I (2004)
11. World Health Organization (WHO). Position paper on pneumococcal vaccines. Weekly Epidemiological Record 78 (2003) 110-119. http://www.who.int/vaccines-documents/PP-WER/wer7814.pdf [available at: http://www.who.int/vaccines-documents/PP-WER/wer7814.pdf [accessed January 1, 2008]]
12. World Health Organization (WHO). Vaccine introduction guidelines (2005), WHO, Geneva
13. ISTAT. Geodemo-Demografia in cifre. Avalable at: http://demo.istat.it.
14. Faustini A., Fano V., Sangalli M., Ferro S., Celesti L., Contegiacomo P., et al. Estimating incidence of bacterial meningitis with capture-recapture method, Lazio Region, Italy. European Journal of Epidemiology 16 (2000) 843-848
15. Curtale F, Ferroni E, Giorgi Rossi P, Guerra MP, Lecci L, Perrella F, Borgia P. Rapporto sul sistema di sorveglianza delle malattie infettive e delle vaccinazioni nel lazio. Anni 2001-2004. Rome: Agenzia di Sanità Pubblica del Lazio; 2005.
16. Giorgi Rossi P., Agabiti N., Faustini A., Ancona A., Tancioni V., Forestiere F., et al. The Burden of hospitalized pneumonia in Lazio, Italy, 1997-1999. The International Journal of Tuberculosis and Lung Disease 8 (2004) 528-536
17. Ispahani P., Slack R.C., Donald F.E., Weston V.C., and Rutter N. Twenty year surveillance of invasive pneumococcal disease in Nottingham: serogroups responsible and implications for immunisation. Archives of Disease in Childhood 89 (2004) 757-762
18. Arditi M., Mason Jr. E.O., Bradley J.S., Tan T.Q., Barson W.J., Schutze G.E., et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics 102 (1998) 1087-1097
19. Kornelisse R.F., Westerbeek C.L.M., Spoor A.B., van der Heijde B., Spanjaard L., Neijens H.J., et al. Pneumococcal meningitis in children: prognostic indicators and outcome. Clinical Infectious Diseases 21 (1995) 1390-1397
20. Mathers C.D., Bernard C., Iburg K.M., Inoue M., Fat D.M., Shibuya K., et al. Global Burden of Disease in 2002: data sources, methods and results (2004), World Health Organization, Geneva
21. Petrou P. Methodological issues raised by preference-based approaches to measuring the health status of children. Health Economics 12 8 (2002) 697-702
22. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children recommendations of the Advisory Committee on Immunization Practices. MMWR. Recommendations and Reports 49 RR09 (2000) 1-38
23. ICONA, Istituto Superiore di Sanità. National infant vaccination coverage in Italy. ICONA; 2003. Rapporti ISTISAN, 03/37.
24. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. The Pediatric Infectious Disease Journal 19 (2000) 187-195
25. Segal N., Leibovitz E., Dagan R., and Leiberman A. Acute otitis media-diagnosis and treatment in the era of antibiotic resistant organisms: updated clinical practice guidelines. International Journal of Pediatric Otorhinolaryngology 69 (2005) 1311-1319
26. Agenzia Italiana del Farmaco (AIFA). Guida all'uso dei farmaci 3 (2003), AIFA, Milano
27. Gagliardi L., Macagno F., Pedrotti D., Coraiola N., Furlan R., Agostini L., et al. Standars antropometrici neonatali prodotti dalla task-force della società italiana di neonatologia e basati su una popolazione italiana nord orientale. Rivista italiana di pediatria 25 (1999) 159-169
28. American Academy of Pediatrics (AAP) and American Academy of Family Physicians (AAFP). Clinical practice guideline. Subcommittee on management of acute otitis media: diagnosis and management of acute otitis media. Pediatrics 113 (2004) 1451-1465
29. Glasziou P.P., Del Mar C.B., Sanders S.L., and Hayem M. Antibiotics for acute otitis media in children. Cochrane Database of Systematic Reviews 1 (2004)
30. National Institute for Clinical Excellence (NICE). Guide to the methods of technology appraisal (2004), NICE, London
31. World Health Organization (WHO). 2001: National Burden of Disease Studies: a practical guide. edition 2.0 (2001), WHO, Geneva
32. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. The New England Journal of Medicine 348 (2003) 1737-1746
33. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297 (2007) 1784-1792
34. Brueggemann A.B., Pai R., Crook D.W., and Beall B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathogens 3 November (11) (2007) e168
35. Melegaro A., and Edmunds W.J. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 22 (2004) 4203-4214
36. Panico M.G., Trinchese N.M., Serpieri B., and Attena F. Italy's new vaccination schedule reduced coverage of poliomyelitis vaccine in Naples. Euro Surveillance 5 (2000) 73-74
37. O'Hagan A., and Stevens J.W. The probability of cost-effectiveness. BMC Medical Research Methodology 2 (2002) 5
38. Giorgi-Rossi P., Ferroni E., Jefferson T., Curtale F., and Borgia P. Streptococcus pneumoniae incidence in western Europe. Author's replay. The Lancet Infectious Diseases 7 (2007) 242-243
39. Beutels P., Thiry N., and Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination-a review (2002-2006). Vaccine 25 (2007) 1355-1367
40. Marchetti M., and Colombo G.L. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy. Vaccine 23 (2005) 4565-4576
41. Salo H., Sintonen H., Pekka Nuorti J., Linna M., Nohynek H., Verho J., et al. Economic evaluation of pneumococcal conjugate vaccination in Finland. Scandinavian Journal of Infectious Diseases 37 (2005) 821-832
42. Asensi F., De Jose M., Lorente M., Moraga F., Ciuryla V., Arikian S., et al. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value in Health 7 (2004) 36-51
43. Butler J.R., McIntyre P., MacIntyre C.R., Gilmour R., Howarth A.L., and Sander B. The cost-effectiveness of pneumococcal conjugate vaccination in Australia. Vaccine 22 (2004) 1138-1149
44. Navas E., Salleras L., Gisbert R., Domìnguez A., Timoner E., Ibanez D., et al. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain). Vaccine 23 (2005) 2342-2348
45. Lloyd A., Patel N., Scott D.A., Runge C., Claes C., and Rose M. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. The European Journal of Health Economics 9 (2008) 7-15
46. Ray G.T., Whitney C.G., Fireman B.H., Ciuryla V., and Black S.B. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. The Pediatric Infectious Disease Journal 25 (2006) 494-501
47. Wisloff T., Abrahamsen T.G., Bergsaker M.A., Lovoll O., Moller P., Pedersen M.K., et al. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine 24 (2006) 5690-5699
48. Severens J.L., and Milne R.J. Discounting health outcomes in economic evaluation: the ongoing debate. Value in Health 7 (2004) 397-401
49. Tasset A., Nguyen V.T., Wood S., and Amazian K. Discounting: technical issues in economic evaluations of vaccination. Vaccine 17 Suppl. (1999) S75-S80
50. Hillman A.L., and Kim M.S. Economic decision making in healthcare. A standard approach to discounting health outcomes. Pharmacoeconomics 7 (1995) 198-205
51. Sheldon T.A. Discounting in health care decisionmaking: time for a change?. Journal of Public Health Medicine 14 (1992) 250-256
52. De Graeve D., and Beutels P. Economic aspects of pneumococcal pneumonia: a review of the literature. Pharmacoeconomics 22 (2004) 719-740
53. McIntosh E.D. Cost-effectiveness studies of pneumococcal conjugate vaccines. Expert Review of Vaccines 3 (2004) 433-442
54. Beutlers P., Bonanni P., Tormans G., Canale F., and Cuneo Crovari P. An economic evaluation of universal pertussis vaccination in Italy. Vaccine 17 (1999) 2400-2409
55. Da Villa G., and Sepe A. Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness. Vaccine 17 (1999) 1734-1738
56. De Campora E., and Pizzuti R. Use of the economic evaluation in the comparison of different vaccination programs against Haemophilus influenzae type b disease. Annali di Igiene 7 (1995) 329-338
57. Gonzalez B.E., Hulten K.G., Lamberth L., Kaplan S.L., Mason E.O., and The U.S. Pediatric Multicenter Pneumococcal Surveillance Group. Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine. The Pediatric Infectious Disease Journal 25 (2006) 301-305
58. Meyerhoff A.S., and Jacobs R.J. Do too many shots due lead to missed vaccination opportunities? Does it matter?. Preventive Medicine 41 August (2005) 540-544
59. Denis F., and Levy-Bruhl D. Mass vaccination against hepatitis B: the French example. Current Topics in Microbiology and Immunology 304 (2006) 115-129